JAK1-IN-31 is a potent and selective JAK1 inhibitor with Ki of 1.9 nM, less potent for JAK3 (Ki=280 nM) and Tyk2 (Ki=12 nM) and no inhibition on hERG and CYP3A4 (IC50>10 uM).

JAK2 inhibitor G5-7 is a small molecule, allosteric JAK2 inhibitor that selectively inhibits JAK2-mediated phosphorylation and activation of EGFR and STAT3 by binding to JAK2.

JAK3i is a selective, covalent JAK3 kinase inhibitor with IC50 of 0.43 nM, shows high selectivity (>3,000-fold) against the closely related kinase domains in JAK1, JAK2, or TYK2, displays 1,300-fold, 600-fold, and 50-fold over EGFR, ITK, and BTK respectiv

JAK3-IN-1 is a potent and selective JAK3 inhibitor with IC50 of 4.8 nM.

JAK-IN-35 is a potent and efficacious dual JAK1/JAK3 inhibitor with IC50 of 0.9/1.9 nM.

Jarin-1 is the first small-molecule inhibitor of JAR1 (IC50=3.8 uM) that inhibits jasmonate responses in Arabidopsis thaliana.

JAS239 is a novel carbocyanine dye that binds and competitively inhibits choline kinase (ChoK) intracellularly, prevents choline phosphorylation and induces cell death in breast cancer cell lines.

JBJ-01-162-04 is a small molecule targeting the flavivirus E protein with broad-spectrum activity, shows activity against DENV in the infectivity assay with IC90 of 0.1 uM.

JBJ-16-111 is a small molecule that inhibits dengue virus (DENV) by binding to its envelope protein E..

JC-171 is a selective NLRP3 inflammasome inhibitor that inhibits LPS/ATP-induced IL-1β release from macrophages with IC50 of 8.45 uM.

JCP251 is a selective small molecule inhibitor of S. aureus serine hydrolase FphB, effectively reduces infectivity in vivo..

JCR 795b is a competitive, small molecule inhibitor of choline kinase (ChoK) with in vitro IC50 of 3.5 uM.

JDTic 2Hcl is a highly selective antagonist for the κ-opioid receptor; without affecting the μ- or δ-opioid receptors.

JF5 (PAR1 inhibitor JF5) is an allosteric inhibitor of PAR1 that binds to helix 8 of the receptor.

JG-231 is an allosteric inhibitor that disrupts the Hsp70-BAG3 interaction (Ki=0.11 uM), inhibits breast cancer cells MCF-7 and MDA-MB-231 with IC50 of 0.12 and 0.25 uM, respectively.

JH-IX-179 is a novel highly potent and selective type I ATP competitive pan-FLT3 inhibitor with IC50 of 4 and 10 nM for FLT3-ITD and D835Y, respectively.

JH-T4 is a potent small molecule SIRT2 inhibitor with IC50 of 0.3 uM (sirtuin deacylation activity), increase intracellular K-Ras4a lysine fatty acylation.

JH-VIII-157-02 is a potent, orally active, CNS-permeable, second-generation inhibitor of ALK G1202R mutant with IC50 of 2 nM, also shows high potency against a variety of other frequently observed mutants (G1269A, S1206Y, F1174L and C1156Y).

JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).

JH-XI-10-02 is a CDK8 PROTAC based on the CDK8 inhibitor JH-VIII-49, induces partial degradation of CDK8 in Jurkat cells with IC50 of 159 nM..

JI130 (JI-130) is a specific Hse1 inhibitor that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone, blocks Hes1-mediated transcriptional repression.

JKA3 inhibitor 31 is a highly potent, selective, reversible, covalent JAK3 inhibitor with IC50 of 49 nM, shows no activity against other JAK kinases.